The Bureau of Internal Revenue committed to submit a consolidated report on Pharmally Pharmaceutical Corporation and government contractors involved in the alleged anomalous billion-peso budget deals in the procurement of pandemic-response medical supplies.
The Senate Blue Ribbon Committee has earlier urged the BIR to form a task force to perform a special audit on taxes padi by government suppliers during the pandemic.
MANILA, Philippines — The revenue agency has started its investigation on Pharmally and other government suppliers, according to a document cited by the head of the Senate Finance Committee Juan Edgardo Angara.
The probe “is being undertaken by concerned revenue district office per memos o the Commissioner issued in September and November,” Angara said.
Based on a conversation with BIR Commissioner Caesar Dulay, Angara explained that the probe is conducted by regional districts because the companies under probe are located in different revenue district offices.
He went on to remark that considering the conditions, conducting a single probe is challenging. The revenue service bureau, on the other hand, stated that a consolidated report will be issued by the end of 2021.
President Rodrigo Duterte told senators earlier that they may imprison Pharmally executives for failing to pay their taxes.
On 28 October, Senate Minority Leader Franklin Drilon stated that Pharmally claimed a tax credit worth ₱96 million in 2020 but failed to pay any tax, citing BIR documents.
He continued saying that a single investigation is difficult to conduct under the circumstances. However, the revenue service bureau said it will come up with a consolidated report by the end of 2021. (RA/JuanManila)